SAM Holdings and EnGeneIC partner to produce EDV-based anti-cancer products

The SGX-listed company gained exclusive global rights for EnGeneIC's EDV theranostics.

The Singapore Institute of Advanced Medicine Holdings (SAM Holdings) and EnGeneIC have formed a strategic partnership to revolutionise the cancer treatment landscape in Asia and provide better outcomes of life for patients.

The partners will collaborate on a profit-sharing basis to produce EDV-based anti-cancer products and develop theranostics for cancer imaging and treatment.

SAM Holdings will help EnGeneIC secure funding and regulatory approvals for building a Singapore plant to manufacture EDV-based products, conduct clinical trials, and obtain marketing authorisation.

In turn, SAM Holdings will receive exclusive distribution and marketing rights in 17 Asian countries.

In addition, SAM Holdings will work with EnGeneIC on pre-clinical testing and regulatory approval of EDV-based theranostics and receive exclusive worldwide distribution rights for these theranostics.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia